Q&A: Page 6

Exclusive interviews with industry leaders

  • Subvariant virus spreading as viral pathogens
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

    President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

    Kelly Bilodeau • Oct. 13, 2022
  • Ameet Mallik horizontal
    Image attribution tooltip
    Permission granted by Ameet Mallik
    Image attribution tooltip

    Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

    The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

    Meagan Parrish • Oct. 12, 2022
  • Young African American biochemist using microscope while working on scientific research in a laboratory. The view is through the glass.
    Image attribution tooltip
    skynesher via Getty Images
    Image attribution tooltip

    Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

    CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

    Karissa Waddick • Oct. 11, 2022
  • Silhouettes of two people colored in a swirling spectrum of colors. They are against a background of other spectrum colors and shapes.
    Image attribution tooltip
    Stan Eales via Getty Images
    Image attribution tooltip

    New partnership may give MDMA an edge in the psychedelics space

    While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses. 

    Kelly Bilodeau • Oct. 10, 2022
  • Professional headshot of Erin Duffy
    Image attribution tooltip

    Permission granted by Asia Kepka

    Image attribution tooltip

    Her antibiotic company failed. Now she’s helping others avoid the same fate.

    The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.

    Karissa Waddick • Oct. 6, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    It’s electric — speeding up the cell therapy process for scalability

    To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

    Alexandra Pecci • Oct. 4, 2022
  • digital clinical trials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that

    The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.

    PharmaVoice staff • Oct. 3, 2022
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip

    Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

    Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

    Michael Gibney • Oct. 3, 2022
  • magic mushroom
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

    The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

    Meagan Parrish • Sept. 27, 2022
  • Autism stock
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Why precision medicine could be the next frontier in treating autism

    Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

    Kelly Bilodeau • Sept. 27, 2022
  • Mobile phone medical doctor
    Image attribution tooltip
    NanoStockk via Getty Images
    Image attribution tooltip

    That’s not Angry Birds — that’s your doctor learning about novel drugs through gaming

    How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.

    Alexandra Pecci • Sept. 26, 2022
  • Brian Goff stands laughing in the forefront, with a crowded room of business attire-clad people in the background.
    Image attribution tooltip

    Permission granted by Brian Goff. 

    Image attribution tooltip

    First 90 Days: Agios Pharmaceuticals’ Brian Goff

    The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.

    Alexandra Pecci • Aug. 22, 2022
  • Seen from behind, a clinician is using a cell phone and checking a patient's electronic health record on a laptop.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How real world evidence is impacting rare disease drug development

    ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

    Kim Ribbink • Aug. 9, 2022
  • Catherine Owen
    Image attribution tooltip

    Permission granted by Catherine Owen.

    Image attribution tooltip

    A glimpse inside Bristol Myers Squibb’s integration with Celgene

    Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

    Meagan Parrish • Aug. 1, 2022
  • Artifical intelligence
    Image attribution tooltip
    Olemedia via Getty Images
    Image attribution tooltip

    How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

    WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

    Kim Ribbink • Aug. 1, 2022
  • A nurse in green scrubs puts a smart watch on a patient in a grey, blue and orange striped shirt.
    Image attribution tooltip
    Giuseppe Lombardo via Getty Images
    Image attribution tooltip

    Personalized data could bring PhysIQ to the forefront of clinical trial evolution

    The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

    Karissa Waddick • July 28, 2022
  • long covid
    Image attribution tooltip
    Lisa Maree Williams via Getty Images
    Image attribution tooltip

    Lupus discovery lends clues to the fight against long COVID

    So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.

    Kelly Bilodeau • July 27, 2022
  • A man walks out of the Pfizer world headquarters building.
    Image attribution tooltip
    Chris Hondros / Staff via Getty Images
    Image attribution tooltip

    Behind Pfizer's new quest to target a 'transformation' in pharma

    A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

    Kelly Bilodeau • July 25, 2022
  • gene therapy
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Anjarium Biosciences’ CEO on its next-gen gene therapies

    Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.

    Kim Ribbink • July 15, 2022
  • A black stethoscope rests diagonally on a rainbow flag background.
    Image attribution tooltip
    Sasirin Pamai via Getty Images
    Image attribution tooltip

    Janssen extends LGBTQ mental health outreach beyond Pride Month

    The pharma giant’s ‘Depression looks like me’ campaign assembles a ‘one stop shop’ of resources to help combat high rates of severe depression in the LGBTQ community.

    Karissa Waddick • July 14, 2022
  • Two packets of pills and a vaccine vials sit atop a blue surgical mask.
    Image attribution tooltip
    Anna Kim via Getty Images
    Image attribution tooltip

    COVID won't evolve to become 'less deadly' — and RedHill is prepping for the long haul

    RedHill Biopharma’s chief operating officer, Guy Goldberg, says the company’s oral COVID-19 therapy could still be needed on a global scale.

    Kim Ribbink • July 12, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing

    Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.

    Meagan Parrish • July 7, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

    As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

    Kim Ribbink • June 30, 2022
  • Katalin Kariko and Drew Weissman
    Image attribution tooltip
    Permission granted by University of Pennsylvania
    Image attribution tooltip

    The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman

    The two Penn Medicine researchers whose work brought the mRNA vaccines into COVID-19 fruition want to see the pharma world embrace early science.

    Michael Gibney • June 29, 2022
  • Image attribution tooltip

    Permission granted by Dan Vahdat.

    Image attribution tooltip

    'Nobel Prize of pharma' helps put Huma's digital health platform on the global map

    The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.

    Kim Ribbink • June 23, 2022